Shareholder Reductions - Zhang Fan from 壹网壹创 plans to reduce his holdings by no more than 2.5% [1] - Yan Jun, honorary chairman and chief scientist of 航宇微, intends to reduce his holdings by no more than 1.66% [1] - 长安信托·中保投1号信托, a shareholder of 紫光股份, plans to reduce its holdings by no more than 1% [1] - Jiang Shuguang, deputy general manager of 崇达技术, plans to reduce his holdings by no more than 200,000 shares [1] - 热景生物 intends to sell back repurchased shares not exceeding 1.8542 million shares [1] - Yuan Meihe, a shareholder of 欧科亿, plans to reduce his holdings by no more than 1.89% [1] - Zhu Fengxue and his concerted actions from 中曼石油 will collectively reduce their holdings by 0.35% [1] - Tokyo Guorui, a shareholder of 燕东微, has already reduced its holdings by 0.88% [1] - Huaguang New Materials' shareholder, Huan Guang Investment, has cumulatively reduced its holdings by 1.60% [1] - Jiayuan Group has reduced its holdings in 吉祥航空 by 8.6065 million shares [1] - Longgao Electric New from 富特科技 has cumulatively reduced its holdings by 1.00% [1] - Actual controller Shi Huiqing from 可川科技 has reduced his holdings by 1.05% [1] - Lu Xinchun, a shareholder of 华海清科, has reduced his holdings by 3.3156 million shares [1] Other Corporate Actions - 建设机械 has terminated the issuance of shares to specific objects [1] - 蒋伟, the controlling shareholder of 吴海生科, has been fined 14.6292 million yuan by the China Securities Regulatory Commission [1]

Core Viewpoint - The company has significantly increased the prices of its cutting tools, which allows for better cost transmission to downstream customers, while also benefiting from product structure upgrades and raw material inventory advantages, leading to further improvement in profitability [1] Group 1 - The company has raised prices for its cutting tool products [1] - The increase in material costs is effectively transmitted to downstream customers [1] - The company's product structure upgrades and raw material inventory advantages are expected to enhance profitability [1]

Summary of Key Points Core Viewpoint - On December 23, several A-share listed companies disclosed their share buyback and reduction plans, indicating varying levels of confidence in their respective companies' future performance [1]. Group 1: Share Buybacks - Bowe Storage has completed a share buyback of 140 million yuan and plans to cancel the repurchased shares [2][3]. - BioShares intends to increase its stake in the company by 50 million to 100 million yuan [2][3]. - Huaxin Cement plans to buy back shares worth no less than 200 million yuan and no more than 400 million yuan [2][3]. - Weimais plans to repurchase shares for an amount between 50 million and 100 million yuan [2][3]. - Nova Star Cloud has secured financing support for a share buyback of up to 135 million yuan [2][3]. Group 2: Share Reductions - Hangyu Micro's shareholders Yan Jun and Wu Yuqi plan to reduce their stakes by no more than 1.66% and 0.36%, respectively [4]. - Yiwang Yichuang's shareholder Zhang Fan intends to reduce his stake by no more than 2.50% [4]. - Quan Feng Technology's fourth-largest shareholder, Hesheng Health, reduced its holdings by 31.89 million shares from December 19 to December 22 [4]. - Unisplendour's shareholder Chang'an Trust plans to reduce its stake by no more than 1% [4]. - Happy Home's shareholder has preliminarily set the transfer price at 19.43 yuan per share [4]. - Okoyi's shareholder Yuan Meihe plans to reduce his stake by no more than 1.89% [4].

智通财经APP讯，欧科亿(688308.SH)发布公告，因股东自身资金需求，公司股东袁美和拟通过集中竞 价或大宗交易方式减持公司股份不超过300万股，即不超过公司目前总股本的1.89%。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 减持主体及持股情况 公告显示，减持主体袁美和为株洲欧科亿控股股东、实际控制人及一致行动人，同时也是直接持股5% 以上股东。截至公告披露日，袁美和持有公司股份2717.0076万股，占公司总股本的17.11%。其持有的 股份来源为首次公开发行前股份（含上市后资本公积金转增股本取得的股份）及通过非交易过户取得股 份，均为无限售条件流通股。 此外，袁美和存在一致行动人谭文清，二者通过签署《一致行动人协议》形成一致行动关系。谭文清当 前持有公司1434.6360万股股份，占总股本的9.01%。 减持计划具体内容 株洲欧科亿数控精密刀具股份有限公司（以下简称"株洲欧科亿"）于2025年12月24日发布股东减持股份 计划公告，公司控股股东、实际控制人之一袁美和因自身资金需求，拟在未来3个月内通过集中竞价或 大宗交易方式减持公司股份不超过300万股，占公司当前总股本的1.89%。 减持时间区间 本次减持将于公告披露之日起15个交易日后的3个月内进行，具体时间为2026年1月19日至2026年4月18 日。其中，通过集中竞价交易方式减持的，在任意连续90日内减持股份总数不超过 ...

Group 1 - Shareholder of Okoyi plans to reduce holdings by up to 1.89% of the company's shares, amounting to a maximum of 3 million shares due to personal funding needs [1] - Tianchuang Fashion is planning a change in control, leading to continued suspension of its stock trading, expected to last no more than 3 trading days [2] - China Electric Power Construction Company reported a new contract amount of 10,317.55 billion yuan for the first 11 months of 2025, a year-on-year decrease of 1.65% [3] Group 2 - Pilin Bio's wholly-owned subsidiary received approval for a clinical trial of a drug, indicating progress in its product development [4] - Yihong Medical obtained two medical device registration certificates for diagnostic kits, enhancing its product portfolio [5] - Aohong Electronics plans to use up to 450 million yuan of idle fundraising for cash management, targeting safe and liquid financial products [6] Group 3 - China Electric Power Construction signed a contract worth approximately 6.626 billion yuan for a natural gas booster station project in Turkey, with a construction period of about 55 months [7] - Baosheng Co. won a bid for a power cable project in Singapore, valued at around 1.2 billion yuan, marking the largest overseas order in its history [8] - *ST Xinyan's stock will resume trading on December 24, 2025, following a capital increase plan that will raise its total share capital to 3.29 billion shares [9] Group 4 - Ningbo Construction's subsidiary signed a construction contract worth 428 million yuan for an engineering project with a duration of 990 days [11] - Lianhuan Pharmaceutical's subsidiary received approval for a drug that passed the consistency evaluation for generic drugs, enhancing its market competitiveness [12] - Zhongjie Automotive received a project designation for a new electric air conditioning compressor, with expected sales of approximately 29.86 million USD over its lifecycle [13] Group 5 - Biopharmaceuticals' major shareholder plans to increase holdings by 50 million to 100 million yuan, indicating confidence in the company's future [14] - Haizheng Pharmaceutical's subsidiary received approval for a veterinary drug product, expanding its product offerings in the animal health sector [15] - *ST Songfa's subsidiary signed contracts for the construction of 8 vessels, with a total contract value between 200 million to 400 million USD [16] Group 6 - Shandong Pharmaceutical Glass announced the resignation of its chairman due to age reasons, indicating a potential leadership transition [17] - Xinno Wei's subsidiary received approval for a clinical trial of a monoclonal antibody drug, indicating advancements in its drug development pipeline [18] - Ningbo Huaxiang's subsidiary secured an order for robot joints, expected to positively impact future business performance [19][20] Group 7 - China Resources Double Crane's subsidiary received approval for a clinical trial of a drug aimed at treating a genetic eye disease, reflecting ongoing R&D efforts [21] - Huaxin Technology's shareholders set a transfer price of 56.69 yuan per share for a block of shares, indicating active shareholder engagement [22] - Xinhua Net announced the resignation of its president due to job relocation, suggesting potential changes in management [23] Group 8 - Taiji Group plans to transfer a 40% stake in a subsidiary to focus on its core pharmaceutical business, enhancing operational efficiency [24] - Huaxin Construction's shareholder plans to increase holdings by 200 million to 400 million yuan, reflecting confidence in the company's prospects [25] - Dongjie Intelligent is planning to issue shares and cash for asset acquisition, with stock trading suspended until further notice [26] Group 9 - Wanrun New Energy was designated as a delivery warehouse for lithium carbonate futures, indicating its strategic position in the market [27] - Prolo Pharmaceutical's subsidiary received a drug registration certificate for an influenza treatment, expanding its product range [28] - Saiwu Technology invested 5 million yuan in a private equity fund focused on smart vehicles and energy innovation, indicating strategic investment in growth sectors [29] Group 10 - Bohui Innovation's subsidiary received approval for a clinical trial of an immunoglobulin drug, indicating progress in its product development [30] - Bohui Innovation's subsidiary also received a drug registration certificate for a coagulation factor product, enhancing its therapeutic offerings [31] - Hanghua Co. plans to allocate 146 million yuan of surplus fundraising for a new green printing materials project, reflecting a commitment to sustainability [32] Group 11 - Nova Star Cloud obtained a loan commitment letter from a bank for a share repurchase plan, indicating financial support for its capital management strategy [33] - Jimin Health established a joint venture for technology innovation, indicating a strategic move to enhance its technological capabilities [34] - Huili Pharmaceutical received a drug registration certificate for a medication used in treating digestive ulcers, expanding its product portfolio [35]

格隆汇12月23日丨欧科亿(688308.SH)公布，因股东自身资金需求，公司股东袁美和先生拟通过集中竞 价或大宗交易方式减持公司股份不超过300万股，即不超过公司目前总股本的1.89%。本次减持将于本 公告披露之日起15个交易日后的3个月内进行，通过集中竞价交易方式减持的，在任意连续90日内，减 持股份的总数不超过公司股份总数的1%；通过大宗交易方式减持的，在任意连续90日内，减持股份的 总数不超过公司股份总数的2%。 ...

人民财讯12月23日电，欧科亿(688308)12月23日公告，股东袁美和持有公司17.11%的股份，拟通过集中 竞价或大宗交易方式，减持公司股份不超过300万股，即不超过公司目前总股本的1.89%。 ...

证券代码：688308 证券简称：欧科亿 公告编号：2025-041 株洲欧科亿数控精密刀具股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： | | 股东名称 | 持有数量（股） | | 持有比例 | 一致行动关系形成原因 | | --- | --- | --- | --- | --- | --- | | 第一组 | | | | | 袁美和先生与谭文清先 | | | 谭文清 | | 14,346,360 | 9.01% | 生签署了《一致行动人协 | | | | | | | 议》 | | | 合计 | | 14,346,360 | 9.01% | — | 股东持股的基本情况 截至本公告披露之日，株洲欧科亿数控精密刀具股份有限公司（以下简称"公 司"）股东袁美和先生持有公司 27,170,076 股股份，占公司总股本的 17.11%。 上述股份为公司首次公开发行前股份（含上市后资本公积金转增股本取得的股份） 及通过非交易过户取得股份，均为无限售条件流通股。 减持计 ...

欧科亿公告，股东袁美和因自身资金需求，拟通过集中竞价或大宗交易方式减持公司股份不超过300万 股，即不超过公司目前总股本的1.89%。本次减持将于本公告披露之日起15个交易日后的3个月内进 行。 ...